- $8.94m
- -$4.16m
- $3.03m
Brief: NeuroMetrix Says Entered Into Termination Agreement With GSK Consumer Healthcare S.A.
Brief: NeuroMetrix Reports That Quell Technology Is To Be Evaluated For Neuromyelitis Optica Spectrum Disorder
Brief: Neurometrix Announces That Top-Line Results From A Randomized Controlled Trial Of Quell® For Treatment Of Fibromyalgia To Be Presented At Two Upcoming Pain Medicine Conferences
Brief: NeuroMetrix Reports Q1 2021 Financial Results
Brief: NeuroMetrix Filed A Prospectus Supplement To Register The Offer And Sale Of $3.85 Million Of Co's Common Stock
Brief: NeuroMetrix Reports Q4 And Full Year 2020 Financial Results
U.S. STOCKS ON THE MOVE-Pfizer, Apple, Tesla, Moderna
U.S. STOCKS ON THE MOVE-Tesla, Kodak, Cancer Genetics, ON Semiconductor
Brief: Neurometrix Reports Q3 2020 Revenue $2.0 Million
U.S. STOCKS ON THE MOVE-SolarEdge Technologies Inc, Snowflake Inc, Koppers Holdings Inc, Fulgent Genetics Inc
NeuroMetrix launches Watch app for its pain management device, shares up
Brief: Neurometrix Inc Announces Launch Of Quell Watch App
Brief: Neurometrix Announces Issuance Of New U.S. Patent For Quell Wearable Technology
Brief: Neurometrix Says Q2 Revenue Fell 42% To $1.4 Million
Brief: Neurometrix Reports DPNcheck Expansion In China
Brief: Neurometrix Signs Dpncheck® Collaboration Agreement With Biomedix
NASDAQ RESUMED AT 01:11 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:06 PM
Brief: Neurometrix Inc Says On June 1, Filed A Prospectus Supplement With SEC To Register Offer And Sale Of $315,000 Of Co's Common Stock